Molecular Partners AG
MOLN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745114
No open-market purchases or sales by Molecular Partners AG insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Molecular Partners AG changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 9 | 9 | 0 |
| Shares | 1.41M | 1.16M | −246.5K (−17.5%) |
| Value | $27.7M | $22.4M | −$5.34M (−19.3%) |
New holders (3)
Institutions that held Molecular Partners AG at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 30,970 | $594.0K | 0.00% |
| UBS Group AG | 3,407 | $65.0K | 0.00% |
| Advisor Group Holdings, Inc. | 200 | $4.00K | 0.00% |
Sold out (3)
Institutions that held Molecular Partners AG at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Sphera Funds Management Ltd. | 80,555 | $1.58M |
| Caas Capital Management LP | 23,071 | $452.0K |
| Monashee Investment Management LLC | 10,000 | $196.0K |